Kidney transplant recipients are predisposed to new-onset diabetes after transplantation (often referred to as NODAT). Medications that promote development of NODAT include glucocorticoids, [...], and the mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus.
Answer
tacrolimus
Question
Kidney transplant recipients are predisposed to new-onset diabetes after transplantation (often referred to as NODAT). Medications that promote development of NODAT include glucocorticoids, [...], and the mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus.
Answer
?
Question
Kidney transplant recipients are predisposed to new-onset diabetes after transplantation (often referred to as NODAT). Medications that promote development of NODAT include glucocorticoids, [...], and the mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus.
Answer
tacrolimus
If you want to change selection, open original toplevel document below and click on "Move attachment"
Parent (intermediate) annotation
Open it Kidney transplant recipients are predisposed to new-onset diabetes after transplantation (often referred to as NODAT). Medications that promote development of NODAT include glucocorticoids, tacrolimus, and the mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus.
Original toplevel document (pdf)
owner: ELBOMBARDO - (no access) - MKSAP_17.pdf, p3418
Summary
status
not learned
measured difficulty
37% [default]
last interval [days]
repetition number in this series
0
memorised on
scheduled repetition
scheduled repetition interval
last repetition or drill
Details
No repetitions
Discussion
Do you want to join discussion? Click here to log in or create user.